In the study conducted by Smith et al., 100% of MDS patients with U2AF1 mutations expressed IRAK4-L, whereas 52% of MDS patients without splicing-factor mutations expressed IRAK4-L [50]. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.